Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
1996
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
2002
Untangling the ErbB signalling network
2001 Standout
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis
2002
MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo
1995
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
2012 Standout
ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency
2000
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
2007
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
1996
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
1999
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
2006 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
1998
Induction of Antagonistic Soluble Decoy Receptor Tyrosine Kinases by Intronic PolyA Activation
2011
Differential Expression of theerbB2 Gene in the Periimplantation Mouse Uterus: Potential Mediator of Signaling by Epidermal Growth Factor-Like Growth Factors1
1997
Evolutionary Analysis of the ErbB Receptor and Ligand Families
2000
Embryo Implantation
2000 Standout
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
2013 Standout
Managing Patients Treated with Bevacizumab Combination Therapy
2005
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Lung Cancer
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
erbBGenes in the Mouse Uterus: Cell-Specific Signaling by Epidermal Growth Factor (EGF) Family of Growth Factors during Implantation
1998
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma
2001
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
EGF–ERBB signalling: towards the systems level
2006 Standout
Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism
2018 Standout
Global epidemiology of hepatitis C virus infection
2005 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987–1999
2002
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
U1 snRNP regulates cancer cell migration and invasion in vitro
2020 Standout
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
2007
Herpes Viruses in Transplant Recipients: HSV, VZV, Human Herpes Viruses, and EBV
2010
A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor
1996
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
2000 Standout
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily
2000
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Nanoparticle and targeted systems for cancer therapy
2004 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Epidermal growth factor receptor (EGFR) signaling in cancer
2005 Standout
Kaposi's Sarcoma
2000 Standout
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Tumor Angiogenesis
2008 Standout
Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers
2003
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
2000 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
2009
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems
2002 Standout
AIDS-Related Malignancies
2003
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
1999
Reduction of Retrovirus-Induced Immunosuppression by In Vivo Modulation of T Cells during Acute Infection
2004 StandoutNobel
Kaposi's Sarcoma-Associated Herpesvirus Utilizes and Manipulates RNA N 6 -Adenosine Methylation To Promote Lytic Replication
2017
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Cancerous stem cells can arise from pediatric brain tumors
2003 Standout
Works of Robert Robles being referenced
A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.
1993
Effect of Antiviral Drugs Used to Treat Cytomegalovirus End-Organ Disease on Subsequent Course of Previously Diagnosed Kaposi's Sarcoma in Patients With AIDS
1999
Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S
2005
A Truncated Intracellular HER2/neu Receptor Produced by Alternative RNA Processing Affects Growth of Human Carcinoma Cells
1993